Jan 29, 2018
Prometic's PBI-4050: Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis (IPF) Finalized
Jan 25, 2018
Prometic to host Key Opinion Leader meeting on novel treatments for idiopathic pulmonary fibrosis (IPF)
Jan 25, 2018
Three Lakes Partners Announces Winners of $1,000,000 IPF Catalyst Challenge
Jan 08, 2018
World's Leading Lung Disease Experts Join Numedii's Idiopathic Pulmonary Fibrosis Advisory Board
Dec 18, 2017
Prometic's Plasminogen (Ryplazim(TM)) granted orphan drug designation for the treatment of idiopathic pulmonary fibrosis (IPF)
Dec 11, 2017
Prometic's PBI-4050 Receives Promising Innovative Medicine (PIM) Designation From The UK MHRA In The Treatment Of Idiopathic Pulmonary Fibrosis
Nov 10, 2017
Results from six-month lung imaging study showed slowing of fibrotic progression in patients with IPF treated with Ofev® versus placebo
Oct 25, 2017
Prometic Receives Fast Track Designation for PBI-4050 in Development for Idiopathic Pulmonary Fibrosis (IPF)
Oct 23, 2017
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Sep 27, 2017
Speakers Set For International Conference On Pulmonary Fibrosis
Sep 21, 2017
Patara Pharma's Phase 2 Study Results for Treatment of Persistent Cough in IPF Patients Published in The Lancet Respiratory Medicine
Sep 21, 2017
American Lung Association stepping up the fight against lesser known Idiopathic Pulmonary Fibrosis, or IPF
Sep 20, 2017
Andre De Grasse and the Canadian Men's Relay Team Pass the Baton to Help Canadians Fight Idiopathic Pulmonary Fibrosis (IPF)
Sep 11, 2017
Results from the INJOURNEY(TM) trial investigating Ofev® with add-on pirfenidone provide new insights into this combination treatment for IPF
Sep 10, 2017
EU-IPFF and Three Lakes Partners Organise Global Advocacy Meeting During ERS Congress in Milan
Aug 07, 2017
Three Lakes Partners Now Accepting Submissions for $1,000,000 IPF Catalyst Challenge
Jun 27, 2017
Veracyte Announces Publication of Study Supporting the Development of Envisia(TM) Genomic Classifier for IPF in Annals of the American Thoracic Society
Jun 06, 2017
Lung Therapeutics, Inc. Raises $14.3 Million Series B Financing to Treat Unmet Needs in Lung Disease and Fibrosis